Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12613-12617

  Kotb, Sameh ^a   Mosharafa, Ashraf ^a   Essawi, Mona ^b   Hassan, Heba ^b   Meshref, Alaa ^a   Morsy, Ahmed ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Biological markers; Diagnosis; miRNAs; Prostate neoplasms

Indexed keywords

MICRORNA 21; MICRORNA 221; PROSTATE SPECIFIC ANTIGEN; MICRORNA; MIRN21 MICRORNA, HUMAN; MIRN221 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROSTATE WEIGHT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION; BLOOD; CANCER GRADING; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY; TUMOR VOLUME;

AGED; EARLY DETECTION OF CANCER; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84925282847     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2584-7     Document Type: Article

References (24)

1. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130–5.
2. Huang X, Liang M, Dittmar R, Wang L. Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci. 2013;14:14785–99.
3. Ribas J, Ni X, Haffner M, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69:7165–9.
4. Waltering K, Porkka K, Jalava S, Urbanucci A, Kohonen P, Latonen L, et al. Androgen regulation of micro-RNAs in prostate cancer. Prostate. 2011;71:604–14.
5. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004;101:11755–60.
6. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012;31:38.
7. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68:8164–72.
8. Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27:4373–9.
9. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS ONE. 2011;6(4):e19139. doi:10.1371/journal.pone.0019139.
10. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282(32):23716–24.
11. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.
12. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80:193–208.
13. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. lnt J Cancer. 2011;128:608–16.
14. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
15. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in sera of prostate cancer patients. Cancer Res. 2011;71:550.
16. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE. 2009;4:e6229.
17. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72:1443–52.
18. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77:1265.e9–16.
19. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71:326–31.
20. Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32:583–8.
21. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469–77.
22. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010;127(2):394–403.
23. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–76.
24. Kang SG, Ha YR, Kim SJ, et al. Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma. Asian J Androl. 2012;14:752–7.